ABSTRACT STI571 is one of the target drugs to Bcr/Abl oncoprotein.It is a special inhibitor to the activation of protein tyrosine kinase by interrupting phosphorylation of substrate.

• 摘 要 STI571 是一种针对Bcr/Abl基因表达产物的靶向治疗药物，可以阻止底物的酪氨酸残基磷酸化，发挥特异性酪氨酸蛋白激酶活性抑制作用，临床研究结果证明对慢性粒细胞白血病的疗效显著优于干扰素及其它化疗药物。